{"id":"https://openalex.org/W1996935441","doi":"https://doi.org/10.1038/nrd3408","title":"Managing the challenge of chemically reactive metabolites in drug development","display_name":"Managing the challenge of chemically reactive metabolites in drug development","publication_year":2011,"publication_date":"2011-04-01","ids":{"openalex":"https://openalex.org/W1996935441","doi":"https://doi.org/10.1038/nrd3408","mag":"1996935441","pmid":"https://pubmed.ncbi.nlm.nih.gov/21455238"},"language":"en","primary_location":{"id":"doi:10.1038/nrd3408","doi":"https://doi.org/10.1038/nrd3408","is_oa":false,"landing_page_url":"https://doi.org/10.1038/nrd3408","pdf_url":null,"source":{"id":"https://openalex.org/S186543748","display_name":"Nature Reviews Drug Discovery","issn_l":"1474-1776","issn":["1474-1776","1474-1784"],"is_oa":false,"is_in_doaj":false,"is_core":true,"listed_in":["anvur-scientific","cwts-core","dongbi-a","doyens","jufo-3","ki-jl-2","medline","norway-2","poland-200","russia-white-list-1","vabb-shw"],"host_organization":"https://openalex.org/P4310319908","host_organization_name":"Nature Portfolio","host_organization_lineage":["https://openalex.org/P4310319908","https://openalex.org/P4310319965"],"host_organization_lineage_names":["Nature Portfolio","Springer Nature"],"type":"journal"},"license":null,"license_id":null,"version":"publishedVersion","is_accepted":true,"is_published":true,"raw_source_name":"Nature Reviews Drug Discovery","raw_type":"journal-article"},"volume":null,"type":"review","is_traditional":true,"indexed_in":["crossref","pubmed"],"open_access":{"is_oa":false,"oa_status":"closed","oa_url":null,"any_repository_has_fulltext":false},"authorships":[{"author_position":"first","author":{"id":"https://openalex.org/A5014454234","display_name":"B. Kevin Park","orcid":"https://orcid.org/0000-0001-8384-824X","observed_orcids":["https://orcid.org/0000-0001-8384-824X"]},"institutions":[{"id":"https://openalex.org/I146655781","display_name":"University of Liverpool","ror":"https://ror.org/04xs57h96","country_code":"GB","type":"education","lineage":["https://openalex.org/I146655781"]}],"countries":["GB"],"is_corresponding":true,"raw_author_name":"B. Kevin Park","raw_affiliation_strings":["MRC Centre for Drug Safety Science, Division of Molecular & Clinical Pharmacology, The Institute of Translational Medicine, University of Liverpool, Liverpool L693GE, UK. B.K.Park@liverpool. ac.uk","Division of Molecular & Clinical Pharmacology, MRC Centre for Drug Safety Science, The Institute of Translational Medicine, University of Liverpool, UK"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"MRC Centre for Drug Safety Science, Division of Molecular & Clinical Pharmacology, The Institute of Translational Medicine, University of Liverpool, Liverpool L693GE, UK. B.K.Park@liverpool. ac.uk","institution_ids":["https://openalex.org/I146655781"]},{"raw_affiliation_string":"Division of Molecular & Clinical Pharmacology, MRC Centre for Drug Safety Science, The Institute of Translational Medicine, University of Liverpool, UK","institution_ids":["https://openalex.org/I146655781"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5071905126","display_name":"Alan R. Boobis","orcid":"https://orcid.org/0000-0003-3371-386X","observed_orcids":["https://orcid.org/0000-0003-3371-386X"]},"institutions":[{"id":"https://openalex.org/I47508984","display_name":"Imperial College London","ror":"https://ror.org/041kmwe10","country_code":"GB","type":"education","lineage":["https://openalex.org/I47508984"]}],"countries":["GB"],"is_corresponding":false,"raw_author_name":"Alan Boobis","raw_affiliation_strings":["Department of Medicine, Imperial College London, South Kensington Campus, SW7 2AZ, London, UK","Department of Medicine Imperial College  London UK"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Department of Medicine, Imperial College London, South Kensington Campus, SW7 2AZ, London, UK","institution_ids":["https://openalex.org/I47508984"]},{"raw_affiliation_string":"Department of Medicine Imperial College  London UK","institution_ids":["https://openalex.org/I47508984"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5039608158","display_name":"Stephen E. Clarke","orcid":"https://orcid.org/0000-0002-3871-0185","observed_orcids":["https://orcid.org/0000-0002-3871-0185"]},"institutions":[{"id":"https://openalex.org/I188950975","display_name":"GlaxoSmithKline (United Kingdom)","ror":"https://ror.org/01xsqw823","country_code":"GB","type":"company","lineage":["https://openalex.org/I188950975"]}],"countries":["GB"],"is_corresponding":false,"raw_author_name":"Stephen Clarke","raw_affiliation_strings":["GlaxoSmithKline, Drug Metabolism and Pharmacokinetics, Ware, SG12 0DP, Hertfordshire, UK","GlaxoSmithKline"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"GlaxoSmithKline, Drug Metabolism and Pharmacokinetics, Ware, SG12 0DP, Hertfordshire, UK","institution_ids":["https://openalex.org/I188950975"]},{"raw_affiliation_string":"GlaxoSmithKline","institution_ids":["https://openalex.org/I188950975"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5022911613","display_name":"Christopher E. Goldring","orcid":"https://orcid.org/0000-0002-8951-2226","observed_orcids":["https://orcid.org/0000-0002-8951-2226","https://orcid.org/0009-0003-9645-6394"]},"institutions":[{"id":"https://openalex.org/I146655781","display_name":"University of Liverpool","ror":"https://ror.org/04xs57h96","country_code":"GB","type":"education","lineage":["https://openalex.org/I146655781"]}],"countries":["GB"],"is_corresponding":false,"raw_author_name":"Chris E. P. Goldring","raw_affiliation_strings":["Division of Molecular & Clinical Pharmacology, MRC Centre for Drug Safety Science, The Institute of Translational Medicine, University of Liverpool, L69 3GE, Liverpool, UK","Division of Molecular & Clinical Pharmacology, MRC Centre for Drug Safety Science, The Institute of Translational Medicine, University of Liverpool, UK"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Division of Molecular & Clinical Pharmacology, MRC Centre for Drug Safety Science, The Institute of Translational Medicine, University of Liverpool, L69 3GE, Liverpool, UK","institution_ids":["https://openalex.org/I146655781"]},{"raw_affiliation_string":"Division of Molecular & Clinical Pharmacology, MRC Centre for Drug Safety Science, The Institute of Translational Medicine, University of Liverpool, UK","institution_ids":["https://openalex.org/I146655781"]}]},{"author_position":"middle","author":{"id":null,"display_name":"David Jones","orcid":null,"observed_orcids":[]},"institutions":[{"id":"https://openalex.org/I4405282191","display_name":"Medicines and Healthcare products Regulatory Agency","ror":"https://ror.org/05fan1e59","country_code":"GB","type":"government","lineage":["https://openalex.org/I4405282191"]}],"countries":["GB"],"is_corresponding":false,"raw_author_name":"David Jones","raw_affiliation_strings":["Medicines and Healthcare Products Regulatory Agency, 151 Buckingham Palace Road, SW1W 9SZ, London, UK","Medicines and Healthcare Products Regulatory Agency UK"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Medicines and Healthcare Products Regulatory Agency, 151 Buckingham Palace Road, SW1W 9SZ, London, UK","institution_ids":["https://openalex.org/I4405282191"]},{"raw_affiliation_string":"Medicines and Healthcare Products Regulatory Agency UK","institution_ids":["https://openalex.org/I4405282191"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5028281331","display_name":"J. Gerry Kenna","orcid":"https://orcid.org/0000-0002-6927-8962","observed_orcids":["https://orcid.org/0000-0002-6927-8962"]},"institutions":[{"id":"https://openalex.org/I105036370","display_name":"AstraZeneca (United Kingdom)","ror":"https://ror.org/04r9x1a08","country_code":"GB","type":"company","lineage":["https://openalex.org/I105036370"]}],"countries":["GB"],"is_corresponding":false,"raw_author_name":"J. Gerry Kenna","raw_affiliation_strings":["Safety Assessment UK, AstraZeneca, Alderley Park, Macclesfield, SK10 4TG, Cheshire, UK","Safety Assessment UK, AstraZeneca, Macclesfield, UK"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Safety Assessment UK, AstraZeneca, Alderley Park, Macclesfield, SK10 4TG, Cheshire, UK","institution_ids":["https://openalex.org/I105036370"]},{"raw_affiliation_string":"Safety Assessment UK, AstraZeneca, Macclesfield, UK","institution_ids":["https://openalex.org/I105036370"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5046049527","display_name":"Craig Lambert","orcid":null,"observed_orcids":[]},"institutions":[{"id":"https://openalex.org/I105036370","display_name":"AstraZeneca (United Kingdom)","ror":"https://ror.org/04r9x1a08","country_code":"GB","type":"company","lineage":["https://openalex.org/I105036370"]}],"countries":["GB"],"is_corresponding":false,"raw_author_name":"Craig Lambert","raw_affiliation_strings":["Clinical Pharmacology and DMPK (Charnwood) AstraZeneca R&D Charnwood, LE11 0RH, Loughborough, UK","AstraZeneca"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Clinical Pharmacology and DMPK (Charnwood) AstraZeneca R&D Charnwood, LE11 0RH, Loughborough, UK","institution_ids":["https://openalex.org/I105036370"]},{"raw_affiliation_string":"AstraZeneca","institution_ids":["https://openalex.org/I105036370"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5111607528","display_name":"Hugh Laverty","orcid":null,"observed_orcids":[]},"institutions":[{"id":"https://openalex.org/I146655781","display_name":"University of Liverpool","ror":"https://ror.org/04xs57h96","country_code":"GB","type":"education","lineage":["https://openalex.org/I146655781"]}],"countries":["GB"],"is_corresponding":false,"raw_author_name":"Hugh G. Laverty","raw_affiliation_strings":["Division of Molecular & Clinical Pharmacology, MRC Centre for Drug Safety Science, The Institute of Translational Medicine, University of Liverpool, L69 3GE, Liverpool, UK","Division of Molecular & Clinical Pharmacology, MRC Centre for Drug Safety Science, The Institute of Translational Medicine, University of Liverpool, UK"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Division of Molecular & Clinical Pharmacology, MRC Centre for Drug Safety Science, The Institute of Translational Medicine, University of Liverpool, L69 3GE, Liverpool, UK","institution_ids":["https://openalex.org/I146655781"]},{"raw_affiliation_string":"Division of Molecular & Clinical Pharmacology, MRC Centre for Drug Safety Science, The Institute of Translational Medicine, University of Liverpool, UK","institution_ids":["https://openalex.org/I146655781"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5041570096","display_name":"Dean John Naisbitt","orcid":"https://orcid.org/0000-0003-4107-7832","observed_orcids":["https://orcid.org/0000-0003-4107-7832"]},"institutions":[{"id":"https://openalex.org/I146655781","display_name":"University of Liverpool","ror":"https://ror.org/04xs57h96","country_code":"GB","type":"education","lineage":["https://openalex.org/I146655781"]}],"countries":["GB"],"is_corresponding":false,"raw_author_name":"Dean J. Naisbitt","raw_affiliation_strings":["Division of Molecular & Clinical Pharmacology, MRC Centre for Drug Safety Science, The Institute of Translational Medicine, University of Liverpool, L69 3GE, Liverpool, UK","Division of Molecular & Clinical Pharmacology, MRC Centre for Drug Safety Science, The Institute of Translational Medicine, University of Liverpool, UK"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Division of Molecular & Clinical Pharmacology, MRC Centre for Drug Safety Science, The Institute of Translational Medicine, University of Liverpool, L69 3GE, Liverpool, UK","institution_ids":["https://openalex.org/I146655781"]},{"raw_affiliation_string":"Division of Molecular & Clinical Pharmacology, MRC Centre for Drug Safety Science, The Institute of Translational Medicine, University of Liverpool, UK","institution_ids":["https://openalex.org/I146655781"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5110269316","display_name":"Sidney D. Nelson","orcid":null,"observed_orcids":[]},"institutions":[{"id":"https://openalex.org/I201448701","display_name":"University of Washington","ror":"https://ror.org/00cvxb145","country_code":"US","type":"education","lineage":["https://openalex.org/I201448701"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"Sidney Nelson","raw_affiliation_strings":["Department of Medicinal Chemistry, University of Washington, Box 357610, Seattle, 98195-7610, Washington, USA","University of Washington"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Department of Medicinal Chemistry, University of Washington, Box 357610, Seattle, 98195-7610, Washington, USA","institution_ids":["https://openalex.org/I201448701"]},{"raw_affiliation_string":"University of Washington","institution_ids":["https://openalex.org/I201448701"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5028459087","display_name":"Deborah A. Nicoll\u2010Griffith","orcid":null,"observed_orcids":[]},"institutions":[{"id":"https://openalex.org/I1285764155","display_name":"Merck & Co., Inc., Rahway, NJ, USA (United States)","ror":"https://ror.org/02891sr49","country_code":"US","type":"company","lineage":["https://openalex.org/I1285764155"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"Deborah A. Nicoll-Griffith","raw_affiliation_strings":["Merck Research Laboratories, 126 East Lincoln Ave, Rahway, 07065, New Jersey, USA","Merck"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Merck Research Laboratories, 126 East Lincoln Ave, Rahway, 07065, New Jersey, USA","institution_ids":["https://openalex.org/I1285764155"]},{"raw_affiliation_string":"Merck","institution_ids":["https://openalex.org/I1285764155"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5027820159","display_name":"Ronald Scott Obach","orcid":"https://orcid.org/0000-0002-6604-401X","observed_orcids":["https://orcid.org/0000-0002-6604-401X"]},"institutions":[{"id":"https://openalex.org/I180857899","display_name":"Pfizer (United States)","ror":"https://ror.org/01xdqrp08","country_code":"US","type":"company","lineage":["https://openalex.org/I180857899"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"R. Scott Obach","raw_affiliation_strings":["Pharmacokinetics, Dynamics and Metabolism, Pfizer, Groton, 06340, Connecticut, USA","Pfizer"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Pharmacokinetics, Dynamics and Metabolism, Pfizer, Groton, 06340, Connecticut, USA","institution_ids":["https://openalex.org/I180857899"]},{"raw_affiliation_string":"Pfizer","institution_ids":["https://openalex.org/I180857899"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5072377747","display_name":"Philip Alexander Routledge","orcid":"https://orcid.org/0000-0001-9770-6787","observed_orcids":["https://orcid.org/0000-0001-9770-6787"]},"institutions":[{"id":"https://openalex.org/I79510175","display_name":"Cardiff University","ror":"https://ror.org/03kk7td41","country_code":"GB","type":"education","lineage":["https://openalex.org/I79510175"]},{"id":"https://openalex.org/I97429440","display_name":"University of Wales","ror":"https://ror.org/01se4f844","country_code":"GB","type":"education","lineage":["https://openalex.org/I97429440"]}],"countries":["GB"],"is_corresponding":false,"raw_author_name":"Philip Routledge","raw_affiliation_strings":["Department of Pharmacology, Therapeutics and Toxicology, Wales College of Medicine, Heath Park, CF14 4XN, Cardiff, UK","Department of Pharmacology, Therapeutics and Toxicology, Wales College of Medicine, Heath Park, UK"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Department of Pharmacology, Therapeutics and Toxicology, Wales College of Medicine, Heath Park, CF14 4XN, Cardiff, UK","institution_ids":["https://openalex.org/I79510175","https://openalex.org/I97429440"]},{"raw_affiliation_string":"Department of Pharmacology, Therapeutics and Toxicology, Wales College of Medicine, Heath Park, UK","institution_ids":[]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5002542670","display_name":"Dennis A. Smith","orcid":"https://orcid.org/0009-0001-7112-7661","observed_orcids":["https://orcid.org/0009-0001-7112-7661"]},"institutions":[{"id":"https://openalex.org/I180857899","display_name":"Pfizer (United States)","ror":"https://ror.org/01xdqrp08","country_code":"US","type":"company","lineage":["https://openalex.org/I180857899"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"Dennis A. Smith","raw_affiliation_strings":["Pharmacokinetics, Dynamics, and Metabolism, Pfizer, Sandwich, CT13 9NJ, Kent, UK","Pfizer"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Pharmacokinetics, Dynamics, and Metabolism, Pfizer, Sandwich, CT13 9NJ, Kent, UK","institution_ids":[]},{"raw_affiliation_string":"Pfizer","institution_ids":["https://openalex.org/I180857899"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5024345070","display_name":"Donald Tweedie","orcid":null,"observed_orcids":[]},"institutions":[{"id":"https://openalex.org/I4210160255","display_name":"Boehringer Ingelheim (United States)","ror":"https://ror.org/05kffp613","country_code":"US","type":"company","lineage":["https://openalex.org/I1330995197","https://openalex.org/I4210160255"]}],"countries":["US"],"is_corresponding":true,"raw_author_name":"Donald J. Tweedie","raw_affiliation_strings":["Boehringer Ingelheim Pharmaceuticals, 900 Ridgebury Road, PO Box 368, Ridgefield, 06877, Connecticut, USA","Boehringer Ingelheim Pharmaceuticals, Ridgefield, USA"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Boehringer Ingelheim Pharmaceuticals, 900 Ridgebury Road, PO Box 368, Ridgefield, 06877, Connecticut, USA","institution_ids":["https://openalex.org/I4210160255"]},{"raw_affiliation_string":"Boehringer Ingelheim Pharmaceuticals, Ridgefield, USA","institution_ids":["https://openalex.org/I4210160255"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5027199677","display_name":"Nico P.E. Vermeulen","orcid":"https://orcid.org/0000-0003-4194-6401","observed_orcids":["https://orcid.org/0000-0003-4194-6401"]},"institutions":[{"id":"https://openalex.org/I865915315","display_name":"Vrije Universiteit Amsterdam","ror":"https://ror.org/008xxew50","country_code":"NL","type":"education","lineage":["https://openalex.org/I865915315"]}],"countries":["NL"],"is_corresponding":false,"raw_author_name":"Nico Vermeulen","raw_affiliation_strings":["Division of Molecular Toxicology, Leiden/Amsterdam Center for Drug Research, Faculty of Sciences, Vrije Universiteit, De Boelelaan 1083, 1081 HV, Amsterdam, The Netherlands","Division of Molecular Toxicology, Leiden/Amsterdam Center for Drug Research, Faculty of Sciences, Vrije Universiteit, The Netherlands"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Division of Molecular Toxicology, Leiden/Amsterdam Center for Drug Research, Faculty of Sciences, Vrije Universiteit, De Boelelaan 1083, 1081 HV, Amsterdam, The Netherlands","institution_ids":["https://openalex.org/I865915315"]},{"raw_affiliation_string":"Division of Molecular Toxicology, Leiden/Amsterdam Center for Drug Research, Faculty of Sciences, Vrije Universiteit, The Netherlands","institution_ids":["https://openalex.org/I865915315"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5063122845","display_name":"Dominic P. Williams","orcid":"https://orcid.org/0000-0002-0758-3152","observed_orcids":["https://orcid.org/0000-0002-0758-3152"]},"institutions":[{"id":"https://openalex.org/I146655781","display_name":"University of Liverpool","ror":"https://ror.org/04xs57h96","country_code":"GB","type":"education","lineage":["https://openalex.org/I146655781"]}],"countries":["GB"],"is_corresponding":false,"raw_author_name":"Dominic P. Williams","raw_affiliation_strings":["Division of Molecular & Clinical Pharmacology, MRC Centre for Drug Safety Science, The Institute of Translational Medicine, University of Liverpool, L69 3GE, Liverpool, UK","Division of Molecular & Clinical Pharmacology, MRC Centre for Drug Safety Science, The Institute of Translational Medicine, University of Liverpool, UK"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Division of Molecular & Clinical Pharmacology, MRC Centre for Drug Safety Science, The Institute of Translational Medicine, University of Liverpool, L69 3GE, Liverpool, UK","institution_ids":["https://openalex.org/I146655781"]},{"raw_affiliation_string":"Division of Molecular & Clinical Pharmacology, MRC Centre for Drug Safety Science, The Institute of Translational Medicine, University of Liverpool, UK","institution_ids":["https://openalex.org/I146655781"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5061761689","display_name":"Ian D. Wilson","orcid":"https://orcid.org/0000-0002-8558-7394","observed_orcids":["https://orcid.org/0000-0002-8558-7394"]},"institutions":[{"id":"https://openalex.org/I105036370","display_name":"AstraZeneca (United Kingdom)","ror":"https://ror.org/04r9x1a08","country_code":"GB","type":"company","lineage":["https://openalex.org/I105036370"]}],"countries":["GB"],"is_corresponding":false,"raw_author_name":"Ian D. Wilson","raw_affiliation_strings":["Clinical Pharmacology and DMPK, AstraZeneca, Alderley Park, Macclesfield, SK10 4TG, Cheshire, UK","AstraZeneca"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Clinical Pharmacology and DMPK, AstraZeneca, Alderley Park, Macclesfield, SK10 4TG, Cheshire, UK","institution_ids":["https://openalex.org/I105036370"]},{"raw_affiliation_string":"AstraZeneca","institution_ids":["https://openalex.org/I105036370"]}]},{"author_position":"last","author":{"id":"https://openalex.org/A5022210942","display_name":"Thomas A. Baillie","orcid":"https://orcid.org/0000-0001-8629-4801","observed_orcids":["https://orcid.org/0000-0001-8629-4801"]},"institutions":[{"id":"https://openalex.org/I201448701","display_name":"University of Washington","ror":"https://ror.org/00cvxb145","country_code":"US","type":"education","lineage":["https://openalex.org/I201448701"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"Thomas A. Baillie","raw_affiliation_strings":["Department of Medicinal Chemistry, School of Pharmacy, University of Washington, 98195, Washington, USA","Department of Medicinal Chemistry, School of Pharmacy, University of Washington, USA"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Department of Medicinal Chemistry, School of Pharmacy, University of Washington, 98195, Washington, USA","institution_ids":["https://openalex.org/I201448701"]},{"raw_affiliation_string":"Department of Medicinal Chemistry, School of Pharmacy, University of Washington, USA","institution_ids":["https://openalex.org/I201448701"]}]}],"institutions":[],"countries_distinct_count":3,"institutions_distinct_count":12,"corresponding_author_ids":["https://openalex.org/A5014454234","https://openalex.org/A5024345070"],"corresponding_institution_ids":["https://openalex.org/I146655781","https://openalex.org/I4210160255"],"apc_list":null,"apc_paid":null,"fwci":6.3634,"has_fulltext":false,"cited_by_count":469,"citation_normalized_percentile":{"value":0.99672131,"is_in_top_1_percent":true,"is_in_top_10_percent":true},"cited_by_percentile_year":{"min":99,"max":100},"biblio":{"volume":"10","issue":"4","first_page":"292","last_page":"306"},"is_retracted":false,"is_paratext":false,"is_xpac":false,"primary_topic":{"id":"https://openalex.org/T10375","display_name":"Pharmacogenetics and Drug Metabolism","score":0.8413000106811523,"subfield":{"id":"https://openalex.org/subfields/3004","display_name":"Pharmacology"},"field":{"id":"https://openalex.org/fields/30","display_name":"Pharmacology, Toxicology and Pharmaceutics"},"domain":{"id":"https://openalex.org/domains/1","display_name":"Life Sciences"}},"topics":[{"id":"https://openalex.org/T10375","display_name":"Pharmacogenetics and Drug Metabolism","score":0.8413000106811523,"subfield":{"id":"https://openalex.org/subfields/3004","display_name":"Pharmacology"},"field":{"id":"https://openalex.org/fields/30","display_name":"Pharmacology, Toxicology and Pharmaceutics"},"domain":{"id":"https://openalex.org/domains/1","display_name":"Life Sciences"}},{"id":"https://openalex.org/T11465","display_name":"Drug-Induced Hepatotoxicity and Protection","score":0.09220000356435776,"subfield":{"id":"https://openalex.org/subfields/3004","display_name":"Pharmacology"},"field":{"id":"https://openalex.org/fields/30","display_name":"Pharmacology, Toxicology and Pharmaceutics"},"domain":{"id":"https://openalex.org/domains/1","display_name":"Life Sciences"}},{"id":"https://openalex.org/T11943","display_name":"Pharmacovigilance and Adverse Drug Reactions","score":0.02889999933540821,"subfield":{"id":"https://openalex.org/subfields/3005","display_name":"Toxicology"},"field":{"id":"https://openalex.org/fields/30","display_name":"Pharmacology, Toxicology and Pharmaceutics"},"domain":{"id":"https://openalex.org/domains/1","display_name":"Life Sciences"}}],"keywords":[{"id":"https://openalex.org/keywords/adverse-drug-reactions","display_name":"adverse drug reactions","score":0.8289999961853027},{"id":"https://openalex.org/keywords/drug-metabolism","display_name":"drug metabolism","score":0.7310000061988831},{"id":"https://openalex.org/keywords/drug-safety-assessment","display_name":"drug safety assessment","score":0.49799999594688416},{"id":"https://openalex.org/keywords/toxicity-assessment","display_name":"toxicity prediction","score":0.3580000102519989},{"id":"https://openalex.org/keywords/chemical-stress","display_name":"chemical stress","score":0.578000009059906},{"id":"https://openalex.org/keywords/clinical-risk-assessment","display_name":"clinical risk assessment","score":0.6380000114440918},{"id":"https://openalex.org/keywords/risk-management","display_name":"risk management","score":0.7279999852180481},{"id":"https://openalex.org/keywords/drug-discovery","display_name":"drug discovery","score":0.43299999833106995},{"id":"https://openalex.org/keywords/clinical-drug-development","display_name":"clinical development","score":0.45399999618530273}],"concepts":[{"id":"https://openalex.org/C74187038","wikidata":"https://www.wikidata.org/wiki/Q1418791","display_name":"Drug discovery","level":2,"score":0.6948139071464539},{"id":"https://openalex.org/C2780035454","wikidata":"https://www.wikidata.org/wiki/Q8386","display_name":"Drug","level":2,"score":0.6226961612701416},{"id":"https://openalex.org/C64903051","wikidata":"https://www.wikidata.org/wiki/Q2198549","display_name":"Drug development","level":3,"score":0.6077320575714111},{"id":"https://openalex.org/C2993432071","wikidata":"https://www.wikidata.org/wiki/Q45959","display_name":"Drug reaction","level":3,"score":0.6066008806228638},{"id":"https://openalex.org/C2779652045","wikidata":"https://www.wikidata.org/wiki/Q507443","display_name":"Pharmaceutical industry","level":2,"score":0.5422878861427307},{"id":"https://openalex.org/C89311334","wikidata":"https://www.wikidata.org/wiki/Q1124842","display_name":"Drug metabolism","level":3,"score":0.5225867033004761},{"id":"https://openalex.org/C2910206359","wikidata":"https://www.wikidata.org/wiki/Q18559532","display_name":"Adverse Outcome Pathway","level":2,"score":0.5076133012771606},{"id":"https://openalex.org/C98274493","wikidata":"https://www.wikidata.org/wiki/Q128406","display_name":"Pharmacology","level":1,"score":0.46858566999435425},{"id":"https://openalex.org/C2777477808","wikidata":"https://www.wikidata.org/wiki/Q407595","display_name":"Metabolite","level":2,"score":0.42682570219039917},{"id":"https://openalex.org/C112930515","wikidata":"https://www.wikidata.org/wiki/Q4389547","display_name":"Risk analysis (engineering)","level":1,"score":0.3800264000892639},{"id":"https://openalex.org/C185592680","wikidata":"https://www.wikidata.org/wiki/Q2329","display_name":"Chemistry","level":0,"score":0.34573641419410706},{"id":"https://openalex.org/C70721500","wikidata":"https://www.wikidata.org/wiki/Q177005","display_name":"Computational biology","level":1,"score":0.3425217270851135},{"id":"https://openalex.org/C71924100","wikidata":"https://www.wikidata.org/wiki/Q11190","display_name":"Medicine","level":0,"score":0.32838451862335205},{"id":"https://openalex.org/C86803240","wikidata":"https://www.wikidata.org/wiki/Q420","display_name":"Biology","level":0,"score":0.18929722905158997},{"id":"https://openalex.org/C55493867","wikidata":"https://www.wikidata.org/wiki/Q7094","display_name":"Biochemistry","level":1,"score":0.12356683611869812}],"mesh":[{"descriptor_ui":"D000818","descriptor_name":"Animals","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D004345","descriptor_name":"Drug Industry","qualifier_ui":"Q000379","qualifier_name":"methods","is_major_topic":false},{"descriptor_ui":"D004364","descriptor_name":"Pharmaceutical Preparations","qualifier_ui":"Q000378","qualifier_name":"metabolism","is_major_topic":true},{"descriptor_ui":"D006801","descriptor_name":"Humans","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D012308","descriptor_name":"Risk Management","qualifier_ui":"Q000379","qualifier_name":"methods","is_major_topic":false},{"descriptor_ui":"D015195","descriptor_name":"Drug Design","qualifier_ui":null,"qualifier_name":null,"is_major_topic":true},{"descriptor_ui":"D018570","descriptor_name":"Risk Assessment","qualifier_ui":"Q000379","qualifier_name":"methods","is_major_topic":false},{"descriptor_ui":"D055808","descriptor_name":"Drug Discovery","qualifier_ui":"Q000379","qualifier_name":"methods","is_major_topic":true},{"descriptor_ui":"D064420","descriptor_name":"Drug-Related Side Effects and Adverse Reactions","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false}],"locations_count":4,"locations":[{"id":"doi:10.1038/nrd3408","doi":"https://doi.org/10.1038/nrd3408","is_oa":false,"landing_page_url":"https://doi.org/10.1038/nrd3408","pdf_url":null,"source":{"id":"https://openalex.org/S186543748","display_name":"Nature Reviews Drug Discovery","issn_l":"1474-1776","issn":["1474-1776","1474-1784"],"is_oa":false,"is_in_doaj":false,"is_core":true,"listed_in":["anvur-scientific","cwts-core","dongbi-a","doyens","jufo-3","ki-jl-2","medline","norway-2","poland-200","russia-white-list-1","vabb-shw"],"host_organization":"https://openalex.org/P4310319908","host_organization_name":"Nature Portfolio","host_organization_lineage":["https://openalex.org/P4310319908","https://openalex.org/P4310319965"],"host_organization_lineage_names":["Nature Portfolio","Springer Nature"],"type":"journal"},"license":null,"license_id":null,"version":"publishedVersion","is_accepted":true,"is_published":true,"raw_source_name":"Nature Reviews Drug Discovery","raw_type":"journal-article"},{"id":"pmid:21455238","doi":null,"is_oa":false,"landing_page_url":"https://pubmed.ncbi.nlm.nih.gov/21455238","pdf_url":null,"source":{"id":"https://openalex.org/S4306525036","display_name":"PubMed","issn_l":null,"issn":null,"is_oa":false,"is_in_doaj":false,"is_core":false,"listed_in":[],"host_organization":"https://openalex.org/I1299303238","host_organization_name":"National Institutes of Health","host_organization_lineage":["https://openalex.org/I1299303238"],"host_organization_lineage_names":[],"type":"repository"},"license":null,"license_id":null,"version":"publishedVersion","is_accepted":true,"is_published":true,"raw_source_name":"Nature reviews. Drug discovery","raw_type":"Journal Article"},{"id":"pmh:oai:research.vu.nl:openaire_cris_publications/ee46dc1f-5c98-4b03-867f-53a918121d8c","doi":null,"is_oa":false,"landing_page_url":"https://hdl.handle.net/1871.1/ee46dc1f-5c98-4b03-867f-53a918121d8c","pdf_url":null,"source":{"id":"https://openalex.org/S4306401107","display_name":"VU Research Portal","issn_l":null,"issn":null,"is_oa":false,"is_in_doaj":false,"is_core":false,"listed_in":[],"host_organization":"https://openalex.org/I865915315","host_organization_name":"Vrije Universiteit Amsterdam","host_organization_lineage":["https://openalex.org/I865915315"],"host_organization_lineage_names":[],"type":"repository"},"license":null,"license_id":null,"version":"submittedVersion","is_accepted":false,"is_published":false,"raw_source_name":"Park, B K, Boobis, A, Clarke, S, Goldring, C E P, Jones, D, Kenna, J G, Lambert, C, Laverty, H G, Naisbitt, D J, Nelson, S, Nicoll-Griffith, D A, Obach, R S, Routledge, P, Smith, D A, Tweedie, D J, Vermeulen, N, Williams, D P, Wilson, I D & Baillie, T A 2011, 'Managing the challenge of chemically reactive metabolites in drug development', Nature Reviews Drug Discovery, vol. 10, no. 4, pp. 292-306. https://doi.org/10.1038/nrd3408","raw_type":"info:eu-repo/semantics/review"},{"id":"pmh:vu:oai:research.vu.nl:publications/ee46dc1f-5c98-4b03-867f-53a918121d8c","doi":null,"is_oa":false,"landing_page_url":"https://research.vu.nl/en/publications/ee46dc1f-5c98-4b03-867f-53a918121d8c","pdf_url":null,"source":{"id":"https://openalex.org/S4306401843","display_name":"Data Archiving and Networked Services (DANS)","issn_l":null,"issn":null,"is_oa":false,"is_in_doaj":false,"is_core":false,"listed_in":[],"host_organization":"https://openalex.org/I1322597698","host_organization_name":"Royal Netherlands Academy of Arts and Sciences","host_organization_lineage":["https://openalex.org/I1322597698"],"host_organization_lineage_names":[],"type":"repository"},"license":null,"license_id":null,"version":"submittedVersion","is_accepted":false,"is_published":false,"raw_source_name":"Nature Reviews Drug Discovery, 10(4), 292 - 306. Nature Publishing Group","raw_type":"info:eu-repo/semantics/other"}],"best_oa_location":null,"sustainable_development_goals":[{"id":"https://metadata.un.org/sdg/3","display_name":"Good health and well-being","score":0.9391000270843506}],"study_designs":[],"awards":[],"funders":[],"has_content":{"grobid_xml":false,"pdf":false},"content_urls":null,"referenced_works_count":92,"referenced_works":["https://openalex.org/W45638005","https://openalex.org/W1482264334","https://openalex.org/W1594216352","https://openalex.org/W1622697170","https://openalex.org/W1968687693","https://openalex.org/W1974332498","https://openalex.org/W1976185410","https://openalex.org/W1978493656","https://openalex.org/W1978796264","https://openalex.org/W1979167419","https://openalex.org/W1984514509","https://openalex.org/W1987144475","https://openalex.org/W1990699073","https://openalex.org/W1995653643","https://openalex.org/W1996521867","https://openalex.org/W1997798681","https://openalex.org/W1998157094","https://openalex.org/W1998618215","https://openalex.org/W1999587831","https://openalex.org/W2001665244","https://openalex.org/W2002378649","https://openalex.org/W2006521034","https://openalex.org/W2009911964","https://openalex.org/W2010584942","https://openalex.org/W2011071201","https://openalex.org/W2013735700","https://openalex.org/W2017009693","https://openalex.org/W2018123263","https://openalex.org/W2018434594","https://openalex.org/W2025113832","https://openalex.org/W2025645149","https://openalex.org/W2026488328","https://openalex.org/W2028696810","https://openalex.org/W2034445069","https://openalex.org/W2037199975","https://openalex.org/W2050281505","https://openalex.org/W2052546550","https://openalex.org/W2055525658","https://openalex.org/W2057627218","https://openalex.org/W2062934575","https://openalex.org/W2064798207","https://openalex.org/W2070345521","https://openalex.org/W2071867698","https://openalex.org/W2072308065","https://openalex.org/W2072564517","https://openalex.org/W2074910964","https://openalex.org/W2082494827","https://openalex.org/W2082901471","https://openalex.org/W2083266527","https://openalex.org/W2084738123","https://openalex.org/W2092563355","https://openalex.org/W2097634036","https://openalex.org/W2100979412","https://openalex.org/W2101016189","https://openalex.org/W2102722476","https://openalex.org/W2103442158","https://openalex.org/W2111323330","https://openalex.org/W2116184147","https://openalex.org/W2116459155","https://openalex.org/W2117819606","https://openalex.org/W2120553600","https://openalex.org/W2121960436","https://openalex.org/W2123824448","https://openalex.org/W2135302201","https://openalex.org/W2136222747","https://openalex.org/W2136859392","https://openalex.org/W2137146513","https://openalex.org/W2139660254","https://openalex.org/W2140055542","https://openalex.org/W2140639850","https://openalex.org/W2145137957","https://openalex.org/W2149727613","https://openalex.org/W2150256003","https://openalex.org/W2152226036","https://openalex.org/W2153334141","https://openalex.org/W2154119460","https://openalex.org/W2156273681","https://openalex.org/W2157090128","https://openalex.org/W2159301944","https://openalex.org/W2161250034","https://openalex.org/W2163089452","https://openalex.org/W2164740372","https://openalex.org/W2164909389","https://openalex.org/W2165904339","https://openalex.org/W2268946957","https://openalex.org/W2397622552","https://openalex.org/W2411544551","https://openalex.org/W2434767585","https://openalex.org/W2570635802","https://openalex.org/W2994195183","https://openalex.org/W3146286451","https://openalex.org/W4236625789"],"related_works":["https://openalex.org/W4376878789","https://openalex.org/W1498927262","https://openalex.org/W3194389666","https://openalex.org/W2412876788","https://openalex.org/W2131146008","https://openalex.org/W1991405092","https://openalex.org/W1488620935","https://openalex.org/W2098472712","https://openalex.org/W2008261434","https://openalex.org/W1991098749"],"abstract_inverted_index":null,"counts_by_year":[{"year":2026,"cited_by_count":20},{"year":2025,"cited_by_count":24},{"year":2024,"cited_by_count":25},{"year":2023,"cited_by_count":12},{"year":2022,"cited_by_count":17},{"year":2021,"cited_by_count":27},{"year":2020,"cited_by_count":29},{"year":2019,"cited_by_count":30},{"year":2018,"cited_by_count":36},{"year":2017,"cited_by_count":34},{"year":2016,"cited_by_count":34},{"year":2015,"cited_by_count":38},{"year":2014,"cited_by_count":39},{"year":2013,"cited_by_count":34},{"year":2012,"cited_by_count":56}],"updated_date":"2026-11-12T12:28:57.059296","created_date":"2016-06-24T00:00:00"}